SINUS-24 and SINUS-52

In SINUS-52, 51% total improvement in NC score vs 15% improvement with placebo was seen at Week 24 (coprimary endpoint) (n=295, pooled DUPIXENT arms) (-1.25 from a baseline score of 2.46) vs 16% improvement with placebo + INCS (n=153) (-0.38 from a baseline score of 2.38) (LSM difference vs placebo: -0.87 [95% CI: -1.03, -0.71]).^1,4

In SINUS-24, -1.34 improvement in NC score with DUPIXENT vs -0.45 improvement with placebo was seen at Week 24 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=143) and placebo + INCS (n=133): -0.89 (95% CI: -1.07, -0.71) (-1.34 from a baseline score of 2.26 vs -0.45 from a baseline score of 2.45, respectively).¹

Rapid relief in nasal congestion was seen as early as Day 2.^6,a (results are descriptive, definitive conclusions cannot be made as this was a post hoc analysis; data prior to Week 24 were not multiplicity controlled).

^aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).^6,7

Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.

CI, confidence interval; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See the full data on nasal congestion and obstruction